Valuation: GeneNews Ltd

Market Cap 4.21M 3.69M 3.43M 3.15M 5.93M 407M 6.02M 40.82M 15.98M 199M 15.81M 15.47M 687M P/E 2021
-2.2x
P/E 2022 -0.39x
Enterprise Value 6M 5.25M 4.88M 4.48M 8.45M 579M 8.57M 58.11M 22.75M 283M 22.51M 22.03M 978M EV / Sales 2021
3.99x
EV / Sales 2022 1.66x
Free-Float
79.62%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer - 09/08/2016
Investor Relations Contact - -
Director TitleAgeSince
Chairman 72 31/12/1999
Chairman - 18/07/2013
Director/Board Member 92 31/12/1999
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%+26.09% - - 3.51M
-4.89%-7.90%-4.49%+9.27% 48.5B
-0.14%-0.76%+378.26%+605.59% 38.97B
+0.39%+2.79%+8.23%+63.86% 35.43B
-1.54%-4.01%+5.95%-12.99% 33.65B
-0.87%-1.56%-1.43%+29.16% 26.58B
-1.28%-6.20% - - 16.82B
-0.67%-0.21%+10.55%+113.87% 15.18B
+1.32%+2.29%+14.62%+15.52% 13.89B
+0.40%-2.79%+3.58%-31.06% 12.76B
Average -1.10%-1.21%+51.91%+99.15% 26.87B
Weighted average by Cap. -1.08%-1.28%+68.39%+125.34%

Financials

2021 2022
Net sales 5.07M 4.44M 4.12M 3.79M 7.14M 489M 7.24M 49.11M 19.22M 239M 19.03M 18.62M 827M 3.8M 3.33M 3.09M 2.84M 5.35M 366M 5.42M 36.78M 14.39M 179M 14.25M 13.94M 619M
Net income -7.48M -6.56M -6.09M -5.59M -10.54M -722M -10.7M -72.52M -28.38M -353M -28.09M -27.49M -1.22B -11.42M -10M -9.29M -8.53M -16.08M -1.1B -16.31M -111M -43.3M -539M -42.85M -41.93M -1.86B
Net Debt -368K -323K -300K -275K -519K -35.56M -527K -3.57M -1.4M -17.4M -1.38M -1.35M -60.11M 1.78M 1.56M 1.45M 1.33M 2.51M 172M 2.55M 17.29M 6.77M 84.25M 6.7M 6.55M 291M
Logo GeneNews Ltd
StageZero Life Sciences, Ltd. is an integrated healthcare company focused on enhancing the early detection and management of cancer and chronic diseases through advanced molecular diagnostics and clinical interventions. It is developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and for personalized health management, with an initial focus on cancer-related indications. The Company offers early cancer diagnostics and risk stratification via Aristotle, using messenger Ribonucleic Acid (mRNA) technology to identify the molecular signatures of multiple cancer types. Its Care Oncology Clinic provides the COC Protocol, a supervised treatment regimen designed to target multiple metabolic cancer pathways, complementing standard cancer therapies by limiting cancer cell energy supply and use. Additionally, COC offers AVRT, a physician-led telehealth program dedicated to identifying and managing early warning signs of cancer and chronic diseases.
Employees
-